HetrombopagAlternative Names: Hetrombopag olamine; SHR 8735 olamine
Latest Information Update: 11 May 2016
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Mechanism of Action Thrombopoietin stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Idiopathic thrombocytopenic purpura
Most Recent Events
- 11 May 2016 Chemical structure information added
- 01 Nov 2015 Jiangsu HengRui Medicine initiates enrolment in a phase I trial in Idiopathic thrombocytopenic purpura in China (PO) NCT02614846)
- 01 Apr 2014 Jiangsu HengRui Medicine completes a phase I trial in Healthy volunteers in China (NCT02409394)